Document:

Exhibit 10.21

 

	
 
    	
***Text   Omitted and Filed Separately with
    
	
Standard TUFTS MC Form
   Sponsored Research Agreement
    	
the   Securities and Exchange Commission.
    
	
Confidential   Treatment Requested Under
    
	
 
    	
17   C.F.R. Sections 200.80(b)(4) and 230.406.
    

 

	
SPONSOR:
    	
TRACON Pharmaceuticals,   Inc.
    
	
SPONSOR CONTACT:
    	
Charles Theuer, MD, PhD
    
	
PRINCIPAL INVESTIGATOR:
    	
[...***...]
    
	
TUFTS MC CONTACT:
    	
Frederick M. Frankhauser,   JD, MBA
    

 

 

SPONSORED RESEARCH AGREEMENT

 

This Sponsored Research Agreement (together with Exhibits A, B, C and D the “Agreement”) is effective as of December 16, 2014 (“Effective Date”) by and between the Tufts Medical Center, Inc., a not-for-profit Massachusetts corporation having offices at the 800 Washington Street, Box 817, Boston, MA 02111 (“Tufts MC”), and TRACON Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 8910 University Center Lane, Suite 700, San Diego, CA 92122 (“Sponsor”).

 

1.            Background.  Sponsor desires to have Tufts MC undertake a research project in accordance with the scope of work described in Exhibit A attached hereto.  The performance of such research is of mutual interest to Sponsor and Tufts MC, and is consistent with the research goals of Tufts MC as a non-profit, tax-exempt institution.

 

2.            The Research.  Tufts MC agrees to use its reasonable efforts to perform the research program described in Exhibit A (the “Research”).

 

2.1                      Research Term.  The term for performance of the Research will begin with the Effective Date and continue for a period of four months (“Research Term”) and may be extended only by written agreement signed by authorized representatives of the parties.

 

2.2                    Personnel.  The Research will be conducted under the direction of [...***...], (“Principal Investigator”) at the Tufts MC. Sponsor’s technical representative responsible for scientific oversight will be Charles Theuer or such other representative as Sponsor may subsequently designate in writing.

 

2.3                     Reports.  Upon completion of the Research, Principal Investigator will provide Sponsor with a written final report summarizing the Research results (the date of delivery of such final report, the “Delivery Date”).  Sponsor shall have the right to use any and all data contained in the written final report of the Research for any purpose contained in the field as described in the Exclusive License Termsheet (Exhibit D).  Tufts MC shall own the data from or results of the Research.

 

2.4                      Materials.  Sponsor will provide certain materials and related information described in Exhibit A attached hereto (“Sponsor Materials”) to the Principal Investigator at Tufts MC for use in the Research.  Tufts MC hereby acknowledges that, as between Sponsor and Tufts MC, Sponsor is the sole owner or licensee of the Sponsor Materials. Tufts MC shall use the Sponsor Materials, and any information and other materials directly

 

 

***Confidential Treatment Requested

 

 

derived therefrom, solely for the Research.  Tufts MC shall not use the Sponsor Materials, or any information or other materials directly derived therefrom, for any other purpose. Tufts MC shall comply with all laws and governmental rules, regulations and guidelines which are applicable to the Sponsor Materials or the use thereof.  Tufts MC shall not transfer the Sponsor Materials, or any information or other materials directly derived therefrom, to any third party without the prior express written consent of Sponsor. Tufts MC shall limit transfer and disclosure of the Sponsor Materials, and any information or other materials on a need to know basis, as reasonably necessary for the Research, to its employees and agents who are bound in writing with Tufts MC to hold in confidence and not make use of the Sponsor Materials, and such information and other materials, for any purpose other than such purpose. Tufts MC shall notify Sponsor promptly upon discovery of any unauthorized use or disclosure of the Sponsor Materials.  Tufts MC hereby acknowledges that the Sponsor Materials are experimental in nature and that they are provided “AS IS.”  SPONSOR MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE SPONSOR MATERIALS OR THE USE THEREOF.  Tufts MC’s use and evaluation of the Sponsor Materials shall be at its own risk. Tufts MC shall hold harmless and indemnify Sponsor against any and all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs) of every kind arising from the use by Tufts MC of the Sponsor Materials, unless such claims arise as a direct result of the gross negligence or willful misconduct of Sponsor.

 

Tufts MC will provide certain materials and related information described in Exhibit A attached hereto (“Tufts MC Materials”) to Sponsor for use in the Research.  Sponsor hereby acknowledges that, as between Sponsor and Tufts MC, Tufts MC is the sole owner or licensee of the Tufts MC Materials. Sponsor shall use the Tufts MC Materials, and any information and other materials directly derived therefrom, solely for the Research.  Sponsor shall not use the Tufts MC Materials, or any information or other materials directly derived therefrom, for any other purpose. Sponsor shall comply with all laws and governmental rules, regulations and guidelines which are applicable to the Tufts MC Materials or the use thereof.  Sponsor shall not transfer the Tufts MC Materials, or any information or other materials directly derived therefrom, to any third party without the prior express written consent of Tufts MC. Sponsor shall limit transfer and disclosure of the Tufts MC Materials, and any information or other materials on a need to know basis, as reasonably necessary for the Research, to its employees and agents who are bound in writing with Sponsor to hold in confidence and not make use of the Tufts MC Materials, and such information and other materials, for any purpose other than such purpose. Sponsor shall notify Tufts MC promptly upon discovery of any unauthorized use or disclosure of the Tufts MC Materials.  Sponsor hereby acknowledges that the Tufts MC Materials are experimental in nature and that they are provided “AS IS.”  TUFTS MC MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE TUFTS MC MATERIALS OR THE USE THEREOF.  Sponsor’s use and evaluation of the Tufts MC Materials shall be at its own risk. Sponsor shall hold harmless and indemnify Tufts MC against any and all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs) of every kind arising from the use by Sponsor of the Tufts

 

Page 2 of 17

 

MC Materials, unless such claims arise as a direct result of the gross negligence or willful misconduct of Tufts MC.

 

 

3.            Funding.

 

3.1                            Amount of Funding.  As consideration for the conduct of the Research by Tufts MC, Sponsor will fund the Research in accordance with the budget set forth in Exhibit B.  The aggregate of all payments to Tufts MC for the Research (the “Award”) will not exceed the amount set forth in Exhibit B without the prior written agreement of both parties.  Tufts MC will not be obligated to expend funds in excess of the Award to conduct the Research.  Tufts MC will not be required to submit any separate budget justification or confirmation of expenditure to Sponsor in connection with the application of the payments made by Sponsor to Tufts MC under this Agreement.  Payments made by Sponsor under this Agreement are not refundable.

 

3.2                            Payments.  Sponsor will make payments to Tufts MC in accordance with the payment schedule as set forth in Exhibit B.

 

3.3                            Equipment.  Title to equipment provided under this Agreement, or purchased or made by Tufts MC in the performance of the Research will vest in [...***...].

 

4.            Intellectual Property.

 

4.1                            Pre-existing Intellectual Property. Ownership of inventions, discoveries, works of authorship and other developments existing as of the Effective Date hereof, and all patents, copyrights, trade secret rights and other intellectual property rights therein (collectively, “Pre-existing Intellectual Property”), are not affected by this Agreement, and neither party shall have any claims to or rights in any Pre-existing Intellectual Property of the other party, except as may be otherwise expressly provided in Exhibit D, upon execution between the parties. Notwithstanding the foregoing, the Pre-existing Intellectual Property of Tufts MC shall be further described in Exhibit C and shall hereinafter be referred to as “Tufts MC Pre-existing Intellectual Property”.

 

4.2                           Disclosure and Ownership.  Tufts MC will promptly disclose to Sponsor all inventions, discoveries, improvements, designs, processes, formulations, products, computer programs, works of authorship, databases, mask works, trade secrets, and know-how (whether or not patentable or subject to copyright or trade secret protection) first conceived or reduced to practice during the performance of the Research (each an “Invention”). Inventorship of all Inventions will be determined in accordance with United States patent law whether or not the Invention is patentable.  Ownership shall follow inventorship.  Inventions that are solely conceived or reduced to practice by employees of Tufts MC will be solely owned by Tufts MC (“Tufts MC Inventions”).  Inventions that are jointly conceived or reduced to practice by employees of Tufts MC and of Sponsor will be jointly owned (“Joint Inventions”).

 

 

***Confidential Treatment Requested

 

Page 3 of 17

 

4.3                            Patents.

 

4.3.1                Tufts MC Inventions.  Upon Sponsor’s written request and at Sponsor’s expense, Tufts MC will cause patent applications to be filed and prosecuted on any patentable Tufts MC Invention.  Alternatively, Tufts MC may notify Sponsor of its intent to file a patent application for a patentable Tufts MC Invention.  If Sponsor does not agree, within [...***...] days after such notification, to pay for the reasonable costs to file, prosecute and maintain patent application(s) covering such Tufts MC Invention, Tufts MC may file at its own expense and Sponsor will have no further rights to such Tufts MC Invention.

 

4.3.2               Joint Inventions.  Tufts MC and Sponsor will discuss whether to file, prosecute and maintain patent applications and patents on any Joint Invention within [...***...] days after invention disclosure. If Sponsor and Tufts MC agree to file patent applications on any Joint Invention, Sponsor will, at its own expense, fie, prosecute and maintain any patent application or patent covering a Joint Invention. Sponsor and Tufts MC agree that the final decisions on the scope and content of all patent applications covering Joint Inventions and their prosecution will be made jointly by Sponsor and Tufts MC within [...***...] days.  If Sponsor elects not to file a patent application for any Joint Invention, Tufts MC may, at its option, elect to file, prosecute and maintain patent applications and patents on such Joint Invention at Tufts MC’s own expense, and Sponsor will have no rights to Tufts MC’s interest in such Joint Invention, including under Sections 4.5 and 4.6 below.  As joint owners of Joint Inventions, each of Tufts MC and Sponsor may practice and grant others the right to practice Joint Inventions without the consent of or a duty of accounting to the other party, subject to Sections 4.4 and 4.5 and the parties’ Agreement identified in Exhibit D.

 

4.3.3              Patent Cooperation. Tufts MC will provide Sponsor with copies of all material documentation with respect to patent applications paid for by Sponsor and will consult with Sponsor with respect to the content thereof.  Sponsor agrees that final decisions on the scope and content of all patent applications covering Tufts MC Inventions and their prosecution will be made by Tufts MC.

 

4.4                            Licenses to Tufts MC Inventions.  Tufts MC hereby agrees to grant to Sponsor an exclusive license to use any Tufts MC Invention and Tufts MC’s ownership interest in any Joint Invention pursuant to the parties’ Agreement in Exhibit D, the “Exclusive License Termsheet”.

 

4.5                          Option.  Subject to Tufts MC’s obligations to the U.S. Government, Tufts MC hereby grants to Sponsor a first option to include any patentable Tufts MC Invention or to Tufts MC’s ownership interest in any patentable Joint Invention (the “Option”) in the parties’ Agreement identified in Exhibit D, the “Exclusive License Termsheet”.  The 

 

 

***Confidential Treatment Requested

 

Page 4 of 17

 

Option will extend for a period of [...***...] days from the later of (a) the date of disclosure of the Invention to Sponsor or (b) the Delivery Date (the “Option Period”).

 

4.6                           Option Exercise.  In order to exercise the Option with respect to a specific Invention, Sponsor must have previously paid or reimbursed Tufts MC for the reasonable expenses incurred by Tufts MC, if any, for the patent filing, prosecution and maintenance for the identified Invention.  Sponsor will notify Tufts MC in writing prior to the end of the Option Period if it wishes to exercise the Option with respect to a specifically identified Invention.  Upon receipt of such notice, Tufts MC agrees to include Tufts MC Invention or Tufts MC’s ownership interest in any patentable Joint Invention in the negotiated terms of License Agreement identified in Exhibit D, the “Exclusive License Termsheet.”

 

4.7                            Licenses to Tufts MC’s Pre-existing Intellectual Property. Tufts MC hereby agrees to grant to Sponsor an exclusive, paid-up license, to use any Tufts MC’s Pre-existing Intellectual Property during the term of this Agreement in accordance with terms described in Exhibit D (“Exclusive License Termsheet”). Notwithstanding the foregoing, the parties also agree to negotiate in good faith to separately complete an exclusive royalty-bearing license to Tufts MC’s Pre-existing Intellectual Property and the terms of such an exclusive license will be based upon the Exclusive License Termsheet, and anticipate concluding such exclusive license within [...***...] days after the Delivery Date.

 

 

5.                                   Confidentiality.  It is anticipated that in the performance of this Agreement, Principal Investigator, Sponsor and Tufts MC may need to disclose to each other information, which is considered confidential.  The rights and obligations of the parties with respect to such information are as follows:  “Disclosing Party” shall mean a party that discloses Confidential Information under this Agreement.  “Receiving Party” shall mean a party that receives Confidential Information under this Agreement.  “Confidential Information” refers to information of any kind, other than data from or results of the Research, which is obtained by Receiving Party from Disclosing Party, which, by appropriate marking, is identified as confidential at the time of disclosure.  In the event that Confidential Information must be provided visually or orally, obligations of confidence shall attach only to that information which is confirmed by Disclosing Party in writing within thirty (30) working days as being confidential.

 

For a period of five (5) years after the Effective Date of this Agreement, Receiving Party agrees to use reasonable efforts, no less than the protection given their own confidential information, to use Confidential Information received from Disclosing Party and accepted by Receiving Party only in accordance with this Section 5.

 

Notwithstanding the foregoing, the obligations of nondisclosure and non-use set forth above will not apply to information received by either party to this Agreement to the extent that such information:

 

 

***Confidential Treatment Requested

 

Page 5 of 17

 

(a)                 was known to the Receiving Party;

(b)                thereafter becomes, through no fault of the Receiving Party, generally available to the public;

(c)               was received by the Receiving Party from a third party not under an obligation of confidentiality to the Disclosing Party; or

(d)             was independently developed by employees of the Receiving Party having no access to or knowledge of the Disclosing Party’s confidential information.

 

If required, Receiving Party may disclose the Disclosing Party’s confidential information to a governmental authority or by order of a court of competent jurisdiction, provided that such disclosure is subject to all applicable governmental or judicial protection available for like information and reasonable advance notice is given to the Disclosing Party.

 

6.            Use of Names.  Neither party will use the name or insignia, or any adaptation thereof, of the other party, or the name of any respective employee or agent, in any form of publicity or promotion without the prior written permission of the other.  For Tufts MC, requests for permission will be directed in writing to the Director, Grants and Contracts, Tufts Medical Center, Inc., 800 Washington Street, Box 817, Boston, MA 02111. This restriction does not apply to standard internal reporting requirements of either party.

 

7.            Publication.  The Tufts MC participants in the Research have the right, at their sole discretion, to publish any results arising from the Research.  In order to provide SPONSOR an opportunity to determine if any such publications contain patentable Inventions or SPONSOR Confidential Information, TUFTS MC will furnish SPONSOR with a copy of any proposed publication [...***...] days in advance of the proposed submission date.  If any such publication contains patentable Inventions, Tufts MC and Sponsor will cooperate regarding filing a patent application within [...***...] days on such Inventions prior to publication in accordance with Section 4.3 and, at Sponsor’s request, will remove any Sponsor Confidential Information.

 

7.1    Filing of this Agreement. The Parties will coordinate in advance with each other in connection with the filing of this Agreement (including redaction of certain provisions of this Agreement) with the SEC or any stock exchange or governmental agency on which securities issued by a Party or its Affiliate are traded, and each Party will use reasonable efforts to seek confidential treatment for the terms proposed to be redacted; provided that each Party will ultimately retain control over what information to disclose to the SEC or any stock exchange or other governmental agency, as the case may be, and provided further that the Parties will use their reasonable efforts to file redacted versions with any governing bodies which are consistent with redacted versions previously filed with any other governing bodies. Other than such obligation, neither Party (or its Affiliates) will be obligated to consult with or obtain approval from the other Party with respect to any filings to the SEC or any stock exchange or other governmental agency.

 

 

8.           Warranties.  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS OR IMPLIED, AS TO ANY MATTER

 

 

***Confidential Treatment Requested

 

Page 6 of 17

 

WHATSOEVER, INCLUDING WITHOUT LIMITATION, THE CONDITION, ORIGINALITY OR ACCURACY OF THE RESULTS OF THE RESEARCH OR OF ANY INVENTIONS OR PRODUCTS BASED ON OR INCORPORATING AN INVENTION, WHETHER TANGIBLE OR INTANGIBLE; OR THE OWNERSHIP, NON-INFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF SUCH RESEARCH RESULTS, INVENTIONS OR PRODUCTS. NEITHER PARTY SHALL BE LIABLE FOR ANY DIRECT, CONSEQUENTIAL OR OTHER DAMAGES SUFFERED BY THE OTHER PARTY OR ANY OTHERS RESULTING FROM THE USE OF ANY INVENTION OR PRODUCT BASED ON OR INCORPORATING AN INVENTION.

 

9.            Indemnification and Insurance.

 

9.1                            Indemnification.  Sponsor agrees to indemnify, hold harmless and defend Tufts MC and its current and former directors, governing board members, trustees, officers, faculty, medical and professional staff, employees, students, affiliates and agents and their respective successors, heirs and assigns (collectively, the “Tufts MC Indemnitees”), against any liability, damage, loss or expenses (including reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon the Tufts MC Indemnitees or any of them in connection with any claims, suits, actions, demands or judgments of any third party arising out of performance of the Research in accordance with this Agreement (“Covered Claims”). Sponsor will not be responsible for the indemnification or defense of the Tufts MC Indemnitees to the extent a Covered Claim is caused by the negligence or willful misconduct of any Tufts MC Indemnitees or any breach of this Agreement by Tufts MC.  Tufts MC will notify Sponsor of any Covered Claim hereunder and Sponsor will, at its own expense, provide attorneys reasonably acceptable to Tufts MC to defend against such Covered Claim.  The Tufts MC Indemnitees will cooperate with Sponsor and may, at Tufts MC option and expense, be represented in such action or proceeding by counsel of their own choosing.  Sponsor agrees not to settle any Covered Claim without the written consent of Tufts MC, not to be unreasonably withheld or delayed.

 

9.2                           Insurance. Each party will obtain and maintain, at its sole expense, a comprehensive general commercial liability insurance policy, including broad form contractual liability coverage, for obligations under this Agreement.  Such policy will have a minimum coverage in the amount of $2,000,000 per occurrence.

 

10.               Mutual Representations and Warranties.  Each party represents and warrants to the other party that:

 

(a)                   it is a corporation duly organized and existing under the laws of its state of incorporation and has the power and authority to enter into this Agreement;

 

(b)                  it has taken all necessary action to authorize the execution and delivery of this Agreement, and to authorize the performance of its obligations hereunder; and

 

Page 7 of 17

 

(c)                   to the best of its knowledge execution and delivery of this Agreement and its performance of this Agreement will not result in any breach or violation of, or constitute a default under, any agreement instrument, judgment or order to which it is a party or by which it is bound.

 

11.                Expiration/Termination.

 

11.1                   Expiration.  This Agreement will expire thirty (30) days after the Delivery Date, unless terminated prior to such date in accordance with this Section 11 or extended by written agreement of the parties.

 

11.2                   Termination for Breach.  If Sponsor breaches any of its obligations under this Agreement and fails to remedy such breach within thirty (30) days after receipt of written notice thereof, Tufts MC will have the right to terminate this Agreement as well as any licenses or options granted to Sponsor hereunder.  In the event Tufts MC breaches any of its obligations under this Agreement and fails to remedy such breach within thirty (30) days after receipt of written notice thereof, Sponsor will have the option of terminating this Agreement upon written notice.

 

11.3                   Termination for Specific Cause.  In the event that the Principal Investigator is unavailable or unable to continue direction of the Research for a period in excess of ninety (90) days, Tufts MC will notify Sponsor and may nominate a replacement; if Tufts MC does not nominate a replacement or if that replacement is unsatisfactory to Sponsor, Sponsor may terminate this Agreement upon thirty (30) days written notice and such right to terminate will be Sponsor’s sole remedy at law or in equity therefor.

 

11.4                    Survival of Agreement Terms.  Sections 2.3, 4 through 10, 11.3, 11.4 and 12 of this Agreement will survive any expiration or termination of this Agreement:

 

12.                Miscellaneous

 

12.1                    Force Majeure.  Tufts MC will not be considered in breach of this Agreement to the extent any failure to perform any term or provisions is caused by any reason beyond Tufts MC’s reasonable control, or by reason of any of the following circumstances; labor or employee disturbances or disputes of any kind; accidents; laws, rules or regulations of any government (including, without imitation, export and import regulations); failure to obtain any government approval required; disease; failure of utilities, mechanical breakdowns, material shortages or other similar occurrences; civil disorders or commotions, acts of aggression, vandalism or other similar occurrences or fire, floods, earthquakes or acts of God.

 

12.2                    Assignments.  Neither party may assign this Agreement without the prior written consent of the other party, except that no such consent shall be required for Sponsor to assign this Agreement in connection with the transfer or sale of all or substantially all of the business of Sponsor to a third party, whether by merger, sale

 

Page 8 of 17

 

of stock, sale of assets or otherwise.  Subject to the foregoing, this Agreement will be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns.

 

12.3                   Independent Inquiry.  As between the parties, Sponsor, Tufts MC and the entities and individuals participating in the Research will all be free to engage in similar research and inquiries made independently under other grants, contracts or agreements with or involving parties other than those to this Agreement.

 

12.4                   Waiver. The waiver by either party of a breach or a default of any provision of this Agreement by the other party will not be construed as a waiver of any succeeding breach of the same or any other provision, nor will any delay or omission on the part of either party to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such party.

 

12.5                   Notices. Any notice under this Agreement will be properly addressed to the other party as set forth below and will be (a) hand delivered, (b) mailed, postage prepaid, first class, certified mail, return receipt requested, or (c) sent, shipping prepaid, receipt requested via a reputable courier service.  Either party may change its address to which notices will be sent by giving notice to the other party in accordance with the terms of this Section 12.5.

 

For notices and payment to Tufts MC:

 

Tufts Medical Center, Inc

800 Washington Street, Box 817

Boston, MA 02111

Attn: Grants and Contracts

 

For notices and invoices to Sponsor:

 

TRACON Pharmaceuticals, Inc.

8910 University Center Lane, Suite 700

San Diego, CA 92122

Attn: Chief Executive Officer

 

12.6                 No Agency.  Nothing herein will be deemed to constitute either party as the agent or representative of the other party or both parties as joint venturers or partners for any purpose.  Neither party will be responsible for the acts or omissions of the other party and neither party will have authority to speak for, represent or obligate the other party in any way without prior written authority from the other party.

 

12.7                   Entire Agreement.  This Agreement contains the full understanding of the parties with respect to the subject matter hereof and supersedes all prior understandings and writings relating thereto.  No waiver, alteration or modification of any of the

 

Page 9 of 17

 

provisions hereof will be binding unless made in writing and signed by the parties by their respective officers thereunto duly authorized. The parties have participated equally in the formation of this Agreement; the language of this Agreement will not be presumptively construed against either party.

 

12.8                   Severability.  In the event that any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict with any law of any relevant jurisdiction, the validity of the remaining provisions will not be affected, and the rights and obligations of the parties will be construed and enforced as if the Agreement did not contain the particular provisions held to be unenforceable.

 

12.9                   Governing Law.  The validity and interpretation of this Agreement and the legal relationship of the parties, will be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to conflict of law rules or principles.

 

12.10           No Oral Modifications.  No change, modification, extension, termination or waiver of this Agreement, or any of its provisions, will be valid unless made in writing and signed by duly authorized representatives of the parties.

 

12.11           Headings.  This Agreement contains headings only for convenience and the headings do not constitute or form a part of this Agreement, and should not be used in the construction of this Agreement.

 

12.12           Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument.

 

 

Remainder of Page Left Blank Intentionally

 

Page 10 of 17

 

IN WITNESS WHEREOF, duly authorized representatives of the parties have executed this Agreement as of the Effective Date.

 

	
 
    	
 
    	
 
    	
 
    	
 
    
	
Tufts Medical Center, Inc.
    	
 
    	
TRACON Pharmaceuticals, Inc.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
/s/ Frederick   Frankhauser, JD, MBA
    	
 
    	
By:
    	
/s/ Charles P. Theuer,   M.D., Ph.D.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
Frederick Frankhauser,   JD, MBA
    	
 
    	
Name:
    	
Charles P. Theuer,   M.D., Ph.D.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
Director, Grants and   Contracts
    	
 
    	
 
    	
Title:
    	
CEO
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    
	
Agreed and accepted by   Principal Investigator with respect to his or her interests and obligations   under this Agreement
    
	
 
    	
 
    	
 
    	
 
    
	
By:
    	
/s/ [...***...]
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
[...***...]
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
12/16/14
    	
 
    	
 
    
													

 

 

***Confidential Treatment Requested

 

Page 11 of 17

 

Exhibit A

Scope of Work

 

[...***...]

 

 

***Confidential Treatment Requested

 

Page 12 of 17

 

[...***...]

 

 

***Confidential Treatment Requested

 

Page 13 of 17

 

[...***...]

 

 

***Confidential Treatment Requested

 

Page 14 of 17

 

Exhibit B

Budget and Payment Schedule

 

 

	
TOTAL BUDGET             non-refundable [...***...]   (Direct and IDC)
    
	
 
    
	
 
    
	
 
    
	
 
    
	
 
    
	
 
    
	
PAYMENT SCHEDULE
    	
 
    	
 
    
	
Non-refundable Full Payment Upon   Execution of Agreement
    	
 
    	
[...***...]
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
TOTAL
    	
 
    	
[...***...]
    

 

 

***Confidential Treatment Requested

 

Page 15 of 17

 

Exhibit C

Tufts MC Pre-existing Intellectual Property

 

[...***...]

 

 

***Confidential Treatment Requested

 

Page 16 of 17

 

Exhibit D

Term Sheet

 

Page 17 of 17

 

***Text Omitted and Filed Separately with

the Securities and Exchange Commission.

Confidential Treatment Requested Under

17 C.F.R. Sections 200.80(b)(4) and 230.406.

 

December 16, 2014

 

CONFIDENTIAL

 

Non-Binding Term Sheet for

Exclusive License Agreement between

Tufts Medical Center and TRACON Pharmaceuticals

 

	
 

Parties
    	
 
    	
 
    	
 

This Term Sheet sets forth, in a non-binding fashion, the current   expression of interest regarding a potential exclusive license agreement by   and between, Tufts Medical Center (“TMC”) and TRACON   Pharmaceuticals, Inc. (“Tracon”). Each of TMC and Tracon may be referred   to as a “Party” and together, the “Parties.”

 

This term   sheet is for discussion purposes only and there will be no binding agreement   or contract between TMC and Tracon unless and until the Agreement (as defined   below) is negotiated and executed by the authorized representatives of each   Party. Notwithstanding the foregoing, the confidentiality provision in this   term sheet shall be binding upon the Parties. 

 
    
	
 

Definitive Agreement*

* in the   event the full value of the [...***...] Sponsored   Research Agreement is not recognized within [...***...] months, the parties will negotiate Agreement to [...***...].

 
    	
 
    	
 
    	
 

The Parties intend in good faith to negotiate a definitive   agreement (the “Agreement”) by the date that is [...***...] days after the date   of delivery of the final report summarizing the Research results under the   Sponsored Research Agreement between the Parties (or such longer period as   agreed by the Parties).
    
	
 

Licensed Patents and Licensed Technology
    	
 
    	
 
    	
 

“Licensed Patents” means:

 

1.             [...***...]

 

2.           [...***...]

 

“Licensed Patents” will include any patent   filings on inventions disclosed by TMC to Tracon on or prior to the effective   date of the Agreement that names either [...***...] or [...***...] as an inventor and   Tracon requests to include in the Agreement.    “Licensed Patents” also includes all divisionals, substitutions,   continued prosecution applications, including requests for continued   examination, continuations, continuations-in-part (to the extent entitled to   the priority date of the parent application), reissues, reexaminations,   extensions, substitutions and counterparts of any of the foregoing patent   applications and patents issued thereon.

 

“Licensed Technology” means the data for Licensed Products or   Licensed Technology Products in the Field of Use to be listed on an exhibit   to the Agreement and which may include unpatented data arising from the   Sponsored Research Agreement between the parties.

 
    
	
 

License Grant
    	
 
    	
 
    	
 

TMC would grant to Tracon an exclusive, worldwide, royalty bearing,   license to the Licensed Patents and the Licensed Technology to make, have   made, use, sell, offer for sale, import, distribute and have distributed the   Licensed Products (the “License”).

 
    

 

 

***Confidential Treatment Requested

 

1

 

December 16, 2014

 

CONFIDENTIAL

 

	
 

Retained Rights
    	
 
    	
 
    	
 

TMC retains the non-exclusive, royalty-free,   perpetual, irrevocable, worldwide right to practice the Licensed Patents and   to use the Licensed Technology, and to allow other non-commercial entities to   practice the Licensed Patents and to use the Licensed Technology, only for   research, educational, scholarly purposes (including collaborations with   other non-profit institutions and government entities) and   for compassionate use purposes. The License shall be subject to any rights   retained by the US government in the Licensed Patents. 

 
    
	
 

Licensed Patented   Product
    	
 
    	
 
    	
 

A therapeutic product (i) developed or made using any product,   process or method claimed by any of the Licensed Patents or (ii) the   manufacture, use or sale of which product would, absent the License, infringe   (or if pending claims were to issue, would infringe) any of the Licensed   Patents.

 
    
	
 

Licensed Technology   Product

 
    	
 
    	
 
    	
 

Any product, process or method which is made, discovered,   optimized, developed or validated through the use of Licensed Technology, or   incorporating Licensed Technology.

 
    
	
 

Licensed Product
    	
 
    	
 
    	
 

Any Licensed Patented Product or Licensed Technology Product.

 
    
	
 

Field of Use
    	
 
    	
 
    	
 

Treatment of human disease.

 
    
	
 

Valid Claim
    	
 
    	
 
    	
 

A claim of an issued and unexpired Licensed Patent, which claim has   not been revoked or held unenforceable or invalid by a decision of a court or   governmental agency of competent jurisdiction from which no further appeal   can be taken, and which has not been disclaimed, denied or admitted to be   invalid or unenforceable through reissue or disclaimer or otherwise.

 
    
	
 

Sublicenses
    	
 
    	
 
    	
 

Tracon may grant sublicenses of the rights granted in the Agreement   provided that such sublicensees are obligated to comply with the terms of the   Agreement as applicable to such sublicense and Tracon provides TMC a copy of   each such sublicense prior to execution of sublicense, and may assign the   Agreement to any third party to whom Tracon sells all or substantially all of   its business or assets in the Field of Use without prior written approval of   TMC.

 
    
	
 

Patent Expenses
    	
 
    	
 
    	
 

·                  “Patent Expenses” means the costs, fees and expenses incurred by   TMC for the preparation, filing, prosecution and/or maintenance of the   Licensed Patents.

 

·                  “Back Patent Expenses” means all Patent Expenses incurred by TMC   prior to the effective date of the Agreement (the “Effective Date”), for   which TMC has not been reimbursed by a third party. Tracon shall reimburse   TMC for all Back Patent Expenses within 30 days of the Effective Date.

 

·                  “Ongoing Patent Expenses” means all Patent Expenses incurred by TMC   from the Effective Date and during the term of the Agreement. Tracon shall   reimburse TMC for [...***...]% of Ongoing   Patent Expenses within 30 days of receipt of invoice from TMC.  [...***...] will be responsible for prosecution   and maintenance of Licensed Patents and will consult regularly with [...***...]   and keep [...***...] reasonably updated and consider in good faith [...***...]’s   comments and suggestions with respect to Licensed Patents.  Tracon may elect to cease reimbursement of   Ongoing Patent Expenses for any particular patent or patent application   within the Licensed Patents in a given country upon prior written notice to   TMC, in which case such patent or patent application shall no longer be   included in the Licensed Patents. For avoidance of doubt, royalty obligations   shall survive as defined in the Royalty Term section of the Agreement. The   Agreement will also include provisions giving Tracon the first right to   enforce the Licensed Patents.

 
    
	
 

Initial License Fee
    	
 
    	
 
    	
 

Tracon shall pay TMC a non-refundable, non-creditable payment of   [...***...] on the Effective Date, payable in cash.

 
    
	
 

License Maintenance Fees
    	
 
    	
 
    	
 

Beginning on the first anniversary of the   Effective Date, Tracon shall pay TMC the non-refundable, non-creditable   amount of [...***...] annually as a license maintenance fee

 
    

 

 

***Confidential Treatment Requested

 

2 of 5

 

December 16, 2014

 

CONFIDENTIAL

 

	
 
    	
 
    	
 
    	
until First   Commercial Sale of the first Licensed Product.

 
    
	
 

Milestone Payments
    	
 
    	
 
    	
 

Tracon shall make the following payments to TMC for the first   Licensed Product achieving the following development milestones (development   milestone and sales milestone payments for a Licensed Product that is [...***...]   shall be at [...***...]% of the amounts indicated):

 
    
	
 
    	
 
    	
 
    	
Development Milestone   Event
    	
Development
   Milestone Payment
    
	
 
    	
 
    	
 
    	
1.        [...***...]

 
    	
[...***...]

 
    
	
 
    	
 
    	
 
    	
2.        [...***...]

 
    	
[...***...]

 
    
	
 
    	
 
    	
 
    	
3.        [...***...]

 
    	
[...***...]

 
    
	
 
    	
 
    	
 
    	
4.        [...***...]

 
    	
[...***...]

 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
Sales Milestone Event
    	
Sales Milestone
   Payment
    
	
 
    	
 
    	
 
    	
[...***....]

 
    	
[...***....]

 
    
	
 

Royalties
    	
 
    	
 
    	
 

Tracon shall pay a royalty to TMC on net sales of each Licensed   Patented Product as set forth in the table below. For royalty payments for   [...***...] Products the royalty rate shall be at [...***...]% of the royalty rates   indicated below.  The Agreement shall   include provisions for the deduction against the royalty due to TMC of   [...***...]% of any royalties, license payments, license fees or similar charges   for intellectual property that is necessary for development, manufacture or   commercialization of Licensed Patented Product or Licensed Technology Product   due to a third party, provided that in no event shall the royalties owed to   TMC in a calendar quarter be less than [...***...]% for a [...***...] Product or   [...***...]% for a [...***...] Product.

 
    
	
 
    	
 
    	
 
    	
 

Net Sales

 
    	
 

Royalty Rate

 
    
	
 
    	
 
    	
 
    	
1.       Net   Sales in a Calendar Year:

 
    	
[...***...]%
    
	
 

Minimum Annual Royalties
    	
 
    	
 
    	
 

·                  $[...***...] per year starting from the   January 1 after First Commercial Sale and thereafter for the remainder   of the Royalty Term.

·                  Non-refundable, but fully creditable against royalties due in the   same calendar year.

 
    
	
 

Royalty Term
    	
 
    	
 
    	
 

Royalties shall be payable on a Licensed Product-by-Licensed   Product and country-by-country basis during the time period during which   royalties are owed (the “Royalty Term”).

 

 

The Royalty Term for a Licensed Product in a given country shall be   the time period commencing on the date of First Commercial Sale of such   Licensed Product in such country and ending on (a) the expiration of the   last Valid Claim covering the manufacture, use in the Field of Use or sale of   such Licensed Product in such country if the Licensed Product is a Licensed   Patented Product but not a Licensed Technology Product, or (b) the 10th anniversary of the First Commercial Sale of   such Licensed 

 
    
						

 

 

***Confidential Treatment Requested

 

3 of 5

 

December 16, 2014

 

CONFIDENTIAL

 

	
 
    	
 
    	
 
    	
 

Product in such country, if the Licensed Product is a Licensed   Technology Product and not a Licensed Patent Product provided,   however, that if (i) the Licensed Product is both a Licensed   Patented Product and a Licensed Technology Product and (ii) the last   Valid Claim covering the manufacture, use in the Field of Use or sale of such   Licensed Product in such country expires earlier than the 10th anniversary of the First Commercial Sale of   such Licensed Product in such country, the term for payment of royalties with   respect to such Licensed Product shall continue until the 10th anniversary of the First Commercial Sale of   such Licensed Product in such country.

 
    
	
 

Sublicense Payments
    	
 
    	
 
    	
 

Tracon shall pay to TMC [...***...]% of sublicense revenues received by   Tracon in consideration of the sublicense of Licensed Patents and Licensed   Technology during the term of the Agreement should such sublicense be first   executed prior to [...***...].  Tracon   shall pay to TMC [...***...]% of sublicense revenues received by Tracon in   consideration of the sublicense of Licensed Patents and Licensed Technology   during the term of the agreement should such sublicense be first executed   after [...***...].

 

Sublicense revenues include upfront and milestone payments and   similar payments made in consideration of the Sublicense of Licensed Patents   and Licensed Technology, but do not include royalty payments or similar   payments (such as profit-sharing payments, in lieu of royalty payments in a   given territory, for example) based on sales of Licensed Products or any   payments for funding or reimbursement for costs of specific research and   development activities conducted by Tracon directly attributable to Licensed   Products subsequent to the execution of and pursuant to such sublicense, for   the provision of goods or services at cost, for debt or equity securities, so   long as said payments reflect the current fair market value of the   securities, as reasonably determined by Tracon’s board of directors, or for   funding or reimbursement of patent filing, prosecution and maintenance costs   incurred by Tracon.  For avoidance of   doubt, payments for debt or equity securities to the extent above FMV of such   securities shall be included in sublicense payments.

 
    
	
 

Tracon Change of Control   Payment
    	
 
    	
 
    	
 

Upon a change of control of Tracon (to be defined in the   Agreement), and assuming that the license agreement between Tracon and Tufts   is still effective, Tracon or its successor shall make a one-time payment to   TMC equal to [...***...], capped at a maximum payment amount of [...***...].

 
    
	
 

Reports
    	
 
    	
 
    	
 

After the First Commercial Sale, Tracon shall provide quarterly   reports to TMC including calculation of royalties.

 
    
	
 

Sponsored Research
    	
 
    	
 
    	
 

Tracon shall enter into a separate Sponsored Research Agreement   with TMC, on or before the Effective Date, to support on-going research   activities in [...***...]’s laboratory related to endoglin’s role in fibrosis.

 
    
	
 

Diligence Obligations
    	
 
    	
 
    	
 

·                  Minimum funding obligations: Tracon shall expend funds on the   development and commercialization of Licensed Products in amounts not less   than the following: (a) [...***...] dollars during the first two years   following the Effective Date and (b) [...***...] dollars during the third   and fourth year following the Effective Date, (clauses (a) and   (b) together, the “Development Expenditures”). Development Expenditures   shall include all research and development expenditures, including sponsored   research payments and contract research, regulatory expenses, and personnel   and external consulting payments, in each case documented and directly   relating to Licensed Products. Tracon agrees to keep Tufts MC informed on an   annual basis of Development Expenditures to support Licensed Products.

·                  Tracon shall use commercially reasonable efforts at its own cost   and expense to develop and commercialize the Licensed Products. 

 
    

 

 

***Confidential Treatment Requested

 

4 of 5

 

December 16, 2014

 

CONFIDENTIAL

 

	
 
    	
 
    	
 
    	
 

·                  Tracon shall achieve the following development events in accordance   with the dates specified in the table below (the “Development Events”),   provided that, if requested by Tracon based upon scientific or other reasons   outside Tracon’s control, which request will include documentation of the   reasons for such request, TMC and Tracon will meet and discuss in good faith   a reasonable extension of such dates in light of such reasons:

 

·                  Regulatory delays

·                  Pre-clinical mechanism data (need to discuss in the context of the   SRA work to be conducted)

·                  Manufacturing scale-up issues

 
    
	
 
    	
 
    	
 
    	
Development Event
    	
 

Date

 
    
	
 
    	
 
    	
 
    	
[...***...]

 
    	
[...***...]

 
    
	
 
    	
 
    	
 
    	
[...***...]

 
    	
[...***...]

 
    
	
 

Confidentiality
    	
 
    	
 
    	
 

This term sheet has been prepared with the understanding that its   contents shall remain confidential in accordance with the confidentiality   agreement between the Parties.

 
    
	
 

[...***...] SAB Position
    	
 
    	
 
    	
 

A separate consulting agreement and equity participation agreement   shall be negotiated in good faith for [...***...]’s anticipated role as   scientific advisory board member of Tracon fibrosis programs. 

 
    
	
 

General Provisions
    	
 
    	
 
    	
 

General provisions, including without limitation, limitation of   liability, limited warranty regarding the right to grant the License,   warranty disclaimer, termination, indemnity, insurance, etc.

 

 
    

 

	
TRACON Pharmaceuticals, Inc.
    	
 
    	
Tufts Medical Center
    
	
 
    	
 
    	
 
    
	
/s/ Charles P. Theuer, M.D., Ph.D.
    	
 
    	
/s/ Susan Blanchard
    
	
 
    	
 
    	
 
    
	
16 Dec 2014
    	
 
    	
12/16/14
    
	
 
    	
 
    	
 
    
	
Date
    	
 
    	
Date
    

 

 

***Confidential Treatment Requested

 

5 of 5EX-4.1

 EXHIBIT 4.1 

FIRST AMENDMENT 
 TO

 THIRD AMENDED AND RESTATED CREDIT AGREEMENT 

This FIRST AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT, dated as of December 19, 2014 (this
“Amendment”), is among INTEGRA LIFESCIENCES HOLDINGS CORPORATION, a Delaware corporation (the “Borrower”), the undersigned Lenders (collectively, the “Consenting Lenders”), and BANK OF
AMERICA, N.A., as Administrative Agent (the “Administrative Agent”). 
 PRELIMINARY STATEMENTS: 

 

	(1)	The Borrower, the Administrative Agent and certain financial institutions from time to time party thereto, as lenders (collectively, the “Lenders”) and/or agents, as the case may be, have entered into
that certain Third Amended and Restated Credit Agreement, dated as of July 2, 2014 (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”). The Credit
Agreement, as amended by, and together with this Amendment, and as may be further amended, supplemented or otherwise modified from time to time, is referred to herein as the “Amended Agreement”. Capitalized terms used but not
defined in this Amendment shall have the meanings assigned to them in the Credit Agreement. 

  

	(2)	The Borrower has informed the Administrative Agent that Borrower desires to enter into the SeaSpine Transactions (as defined below) on or about June 30, 2015, and in any event no later than the Outside Date (as
defined below). 

  

	(3)	The Borrower has requested that the Required Lenders amend the Credit Agreement to permit the SeaSpine Transactions upon the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements contained herein, the parties hereto agree
as follows: 
 SECTION 1.01. Amendments. 

(a) Amendment to Section 1.01. Section 1.01 of the Credit Agreement is hereby amended by inserting the
following new defined terms in alphabetical order: 
 “First Amendment Effective Date” means
December 19, 2014. 
 “Integra LifeSciences” means Integra LifeSciences Corporation, a Delaware
corporation, and direct, Wholly-Owned Subsidiary of Borrower. 
 “IsoTis” means IsoTis, Inc., a Delaware
corporation. 

 “IsoTis International” means IsoTis International SA, a
corporation formed under the laws of Switzerland and a Foreign Subsidiary of the Borrower prior to the consummation of the SeaSpine Dividend Transactions. 

“Outside Date” means, with respect to the SeaSpine Transactions, the earlier of (a) December 31,
2015 or (b) the date that the Borrower irrevocably notifies the Administrative Agent in writing that it no longer intends to pursue or consummate the SeaSpine Transactions. 

“Remaining Borrower Companies” means the Borrower and all of its Subsidiaries, other than the SeaSpine
Transaction Companies and each of their respective Subsidiaries. 
 “Remaining Borrower Company Contributed
Assets” means, with respect to the Remaining Borrower Companies, all or any class of assets arising from or primarily related to the spine and orthobiologics business that are transferred, conveyed, sold or contributed to SpinCo or
otherwise transferred, conveyed or disposed of in connection with the SeaSpine Transactions. 
 “SeaSpine”
means SeaSpine, Inc., a Delaware corporation. 
 “SeaSpine Business Assets” means (a) with respect to
any of the SeaSpine Transaction Companies, all or substantially all of their respective assets and (b) with respect to the Remaining Borrower Companies, the Remaining Borrower Company Contributed Assets; provided, that in no event shall
the aggregate book value (as determined based upon the quarterly or annual financial statements, as the case may be, of the Borrower most recently delivered prior to the consummation of the SeaSpine Dividend Transactions) of the total assets of the
SeaSpine Transaction Companies upon the consummation of the SeaSpine Dividend Transaction, including, without limitation, all Remaining Borrower Company Contributed Assets transferred, conveyed, sold or otherwise contributed to any of the SeaSpine
Transaction Companies in connection with the SeaSpine Transactions, constitute more than 25.0% of the aggregate book value (as determined based upon the quarterly or annual financial statements, as the case may be, of the Borrower most recently
delivered prior to the consummation of the SeaSpine Dividend Transactions) of the total assets of the Borrower and all of its Subsidiaries immediately prior to the consummation of the SeaSpine Dividend Transactions; provided, further,
that notwithstanding satisfaction of the total asset test in the foregoing proviso or anything else in this Agreement to the contrary, no more than $50,000,000 in cash may be included as SeaSpine Business Assets of the SeaSpine Transaction Companies
(including Remaining Borrower Company Contributed Assets consisting of cash transferred, conveyed, sold or otherwise contributed to the SeaSpine Transaction Companies) upon the consummation of the SeaSpine Dividend Transactions. 

 “SeaSpine Consolidation Transactions” means (a) in the case
of a SeaSpine Domestic Transaction, the transfer or other conveyance to SpinCo of (i) the Equity Interests of Theken Spine, (ii) the Equity Interests of IsoTis and/or any of its Subsidiaries, (iii) the Equity Interests of SeaSpine,
and (iv) any other SeaSpine Business Assets, in a series of related transactions (which may include Investments, Dispositions, mergers, consolidations and Restricted Payments), plus any other transactions that are acceptable to the Required
Lenders, in each case consummated on or around (but not later than) the date on which the SeaSpine Dividend Transactions are consummated, or (b) in the case of a SeaSpine Foreign Transaction, the transfer or other conveyance to SpinCo of
(i) the Equity Interests of Theken Spine, (ii) the Equity Interests of SeaSpine, and (iii) any other SeaSpine Business Assets, in a series of related transactions (which may include Investments, Dispositions, mergers, consolidations
and Restricted Payments), plus any other transactions that are acceptable to the Required Lenders, in each case consummated on or around (but not later than) the date on which the SeaSpine Dividend Transactions are consummated. 

“SeaSpine Dividend Transactions” means the distribution and/or dividend, in a single transaction or a series
of related transactions occurring after the consummation of the SeaSpine Consolidation Transactions, of all the Equity Interests in SpinCo to the stockholders of the Borrower. 

“SeaSpine Domestic Transaction” means the SeaSpine Consolidation Transactions and SeaSpine Dividend
Transactions consummated using the Domestic Subsidiary described in clause (b) of the definition of “SpinCo”. 

“SeaSpine Foreign Transaction” means the SeaSpine Consolidation Transactions and SeaSpine Dividend
Transactions consummated using the Foreign Subsidiary described in clause (a) of the definition of “SpinCo”. 

“SeaSpine Transaction Companies” means the collective reference to IsoTis, IsoTis International, SeaSpine,
Theken Spine, and any of their Subsidiaries. 
 “SeaSpine Transactions” means the collective reference to
the formation of SpinCo, the merger of IsoTis into Integra LifeSciences, the SeaSpine Dividend Transactions and the SeaSpine Consolidation Transactions, or any of them, as the context may require. 

 “SpinCo” means (a) in the case of a SeaSpine Domestic
Transaction, a Wholly-Owned Subsidiary of Integra LifeSciences that is a Domestic Subsidiary, provided that such Subsidiary shall be deemed to be an Immaterial Subsidiary at all times prior to the Outside Date, or (b) in the case of a SeaSpine
Foreign Transaction, IsoTis International (or any parent company or direct Wholly-Owned Subsidiary thereof in any such case formed on or after the First Amendment Effective Date solely in furtherance of the SeaSpine Transactions, in each case, that
is a Foreign Subsidiary). 
 “Theken Spine” means Theken Spine, LLC, an Ohio limited liability
company.” 
 (b) Amendment to Section 1.01. The definition of “Consolidated EBITDA” is hereby
deleted in its entirety and replaced with the below (for ease of references, changes from the existing definition are reflected in the blackline below): 

““Consolidated EBITDA” means, for any period, for any Person and its Subsidiaries determined on a
consolidated basis, an amount equal to Consolidated Net Income for such period, 
 plus (a) the following (without duplication)
to the extent deducted in calculating such Consolidated Net Income during such period: (i) Consolidated Interest Charges for such period; (ii) the provision for federal, state, local and foreign income taxes payable for such period;
(iii) depreciation and amortization expense; (iv) all charges and other expenses reducing Consolidated Net Income in each case which do not represent a cash item in such period or any future period; (v) cash expenses directly related
to global enterprise resource planning implementation costs for such period, not to exceed (A) an aggregate amount of $17,500,000 per annum during each of the fiscal years ending December 31, 2013 and December 31, 2014, (B) an
aggregate amount of $15,000,000 per annum during the fiscal year ending December 31, 2015, and (C) an aggregate amount of $5,000,000 per annum during each fiscal year ending December 31, 2016 or thereafter; (vi) cash expenses
directly related to the remediation, unplanned idle time and underutilization of Subsidiary manufacturing facilities not to exceed (A) an aggregate amount of $10,000,000 per annum during each of the fiscal years ending December 31, 2013
and December 31, 2014 and (B) an aggregate amount of $5,000,000 during the period commencing on January 1, 2015 and ending on the Maturity Date; (vii) with respect to the fiscal year ending December 31, 2013 only, cash
expenses directly related to the voluntary recall of certain products manufactured in the Anasco, Puerto Rico facility not to exceed $5,000,000 in the aggregate; (viii) cash expenses directly related to the buyout of pension liabilities in an
aggregate amount not to exceed $7,500,000 during the term of this Agreement; (ix) cash expenses actually incurred in connection with restructuring activities (which, for the avoidance of doubt, shall include, without duplication, discontinued
operations, retention, severance, systems establishment costs, excess pension charges, contract termination costs and costs to consolidate facilities and 

 
relocate employees) in an aggregate amount not to exceed (A) $15,000,000 during the fiscal year ending December 31, 2013, (B) $17,500,000 during the fiscal year ending
December 31, 2014, (C) $15,000,000 during the fiscal years ending December 31, 2015 and December 31, 2016, (E) $10,000,000 during the fiscal year ending December 31, 2017 and (F) $5,000,000 during the period
commencing on January 1, 2018 and ending on the Maturity Date; (x) customary fees and expenses paid in cash and actually arising directly from Permitted Acquisitions, Investments, Dispositions, issuances or incurrences of Indebtedness,
issuances of Equity Interests or, modifications of instruments of Indebtedness, or the SeaSpine Transactions, solely with respect to transactions permitted hereunder and actually consummated; (xi) customary costs
and expenses paid in cash and actually arising directly from Permitted Acquisitions, Investments, Dispositions, issuances or incurrences of Indebtedness, issuances of Equity Interests or, modifications of instruments of
Indebtedness, or the SeaSpine Transactions, solely with respect to transactions that were not consummated but would have been permitted hereunder, in an aggregate amount not to exceed $3,000,000; (xii) all payments made to Governmental
Authorities (including with respect to settlements, judgments, fines and penalties) in connection with any investigation disclosed in any public filing made by the Borrower in an aggregate amount not to exceed $10,000,000; (xiii) cash proceeds
of business interruption insurance, in an amount not to exceed the earnings for the applicable period that such proceeds are intended to replace; (xiv) non-recurring milestone payments, royalty payments or upfront payments by any Loan Party
permitted hereunder; (xv) without duplication, any extraordinary, unusual or non-recurring cash losses; (xvi) losses paid in cash in connection with any interest rate or foreign exchange rate Swap Contract permitted hereunder,
(xvii) without duplication, cash expenses, charges and losses if and to the extent such expenses, charges and losses are (A) fully indemnified by a contractual obligation of the seller under a Permitted Acquisition or (B) covered by
insurance (excluding self-insurance), but, in each case, only to the extent, (x) such indemnification obligation or insurance policy remains in full force and effect, (y) such seller is at the time such add-back is taken, and remains,
solvent, and such seller or insurance provider has not refused or challenged a claim for such indemnification or insurance payment and (z) with respect to insurance, such insurance proceeds will be reimbursed with twelve months of the time such
expenses were incurred; provided, that, notwithstanding anything in this definition to the contrary, during any fiscal year ending on December 31, 2014 and thereafter, if and to the extent that the maximum amount of add-backs under any
of the foregoing clauses (a)(v)-a(vii), and (a)(ix) (the “Add Back Provisions”) are not actually applied during such fiscal year for the purpose specified in the applicable Add-Back Provision, such unused
portion instead may be added to the maximum amount permitted to be added back under any other Add Back Provisions, so long as the aggregate amount of add-backs under all Add Back Provisions during each fiscal year does not exceed the aggregate
maximum amount of all add-backs permitted under the Add Back Provisions for such fiscal year; plus (b) Permitted Cost Savings; and minus (c) the following to the extent included in calculating such Consolidated Net Income:
(i)

 
Federal, state, local and foreign income tax credits of the Borrower and its Subsidiaries for such period; (ii) all non-cash items increasing Consolidated Net Income for such period unless
representing a cash item in any future period; (iii) without duplication, any extraordinary, unusual or non-recurring cash gains; (iv) all indemnification and insurance proceeds received with respect to which an add-back was previously
taken in accordance with clause (a)(xvii) of this definition; and (v) all increases to Consolidated Net Income arising from any interest rate or foreign exchange Swap Contract permitted hereunder. Consolidated EBITDA is subject to
calculation on a Pro Forma Basis in accordance with the provisions in Section 1.03.” 
 (c) Amendment to
Section 1.01. The definition of “Eurodollar Rate” is hereby amended by deleting the period at the end and inserting the following additional proviso: “; and provided, further, that if the Eurodollar Rate shall
be less than zero, such rate shall be deemed zero for purposes of this Agreement.” 
 (d) Amendment to
Section 1.01. The definition of “Permitted Cost Savings” is hereby deleted in its entirety and replaced with the below (for ease of reference, changes from the existing definition are reflected in the blackline below): 

““Permitted Cost Savings” means, for any four quarter measurement period, the projected or anticipated
future synergies, cost savings and restructuring charges expected to arise from any Permitted Acquisition or Disposition or any SeaSpine Transaction permitted hereunder for such period so long as, and only to the extent that, such future
synergies, cost savings and restructuring charges either (a) are permitted to be included as pro forma adjustments under Regulation S-K or Regulation S-X whether or not the pro forma reporting is required under applicable law, or (b) are
certified in writing (which shall include detailed calculations of such amounts and supporting documentation as may be reasonably requested by the Administrative Agent) by the Borrower, so long as (i) in each case under the foregoing clauses
(a) and (b) such synergies, cost savings and restructuring charges are reasonably expected to be realized within eighteen (18) months after such Permitted Acquisition, permitted Disposition or permitted
DispositionSeaSpine Transaction, and (ii) the aggregate amount of all synergies, cost savings and restructuring charges arising under the foregoing clauses (a) and (b) that may be added back to Consolidated
EBITDA of the Borrower and its consolidated Subsidiaries during such measurement period does not exceed the greater of (x) $30,000,000 or (y) 15% of Consolidated EBITDA of the Borrower and its consolidated Subsidiaries (as calculated prior
to giving effect to such Permitted Cost Savings in clause (b) of Consolidated EBITDA).” 
 (e)Amendment to
Section 7.02. Section 7.02 of the Credit Agreement is hereby amended by (i) deleting “and” from the end of clause (q), (ii) replacing the period at the end of clause (r) with “; and”, and
(iii) inserting the following new clause (s): 
 “(s) so long as the Outside Date has not occurred, Investments
contemplated by the definition of “SeaSpine Transactions” and related defined terms.” 

 (f) Amendment to Section 7.04(a)(v). Section 7.04(a)(v) of the
Credit Agreement is hereby deleted in its entirety and replaced with the following (for ease of reference, changes from the existing definition are reflected in the blackline below): 

“(v) a Subsidiary may enter into a Disposition permitted under Sections 7.05(d), (e), (f),
(k) and (kn);” 
 (g) Amendment to Section 7.04(a)(vi).
Section 7.04(a)(vi) of the Credit Agreement is hereby deleted in its entirety and replaced with the following(for ease of reference, changes from the existing definition are reflected in the blackline below): 

“(vi) the Borrower may enter into a Disposition permitted under Sections 7.05(d), (e),
(f)and, (k) and (n);” 
 (h) Amendment to Section 7.05.
Section 7.05 of the Credit Agreement is hereby amended by (i) deleting “and” from the end of clause (l); (ii) replacing the semi-colon at the end of clause (m) with “; and”, and (iii) inserting the
following new clause (n) immediately after clause (m): 
 “(n) so long as the Outside Date has not occurred,
Dispositions contemplated by the definition of “SeaSpine Transactions” and related defined terms.” 
 (i)
Amendment to Section 7.06. Section 7.06 of the Credit Agreement is hereby amended by (i) deleting “and” from the end of clause (l), (ii) replacing the period at the end of clause (m) with “; and”,
and (iii) inserting the following new clause (n): 
 “(n) so long as (i) no Event of Default shall have
occurred and be continuing at the time thereof or would result therefrom, (ii) immediately before and after giving effect to the SeaSpine Dividend Transactions, the Loan Parties shall be in compliance with Section 7.17 on a Pro
Forma Basis, (iii) such transactions shall occur on or prior to the Outside Date, and (iv) prior to or substantially simultaneously with the consummation of the SeaSpine Dividend Transactions, the Borrower shall have delivered to the
Administrative Agent (A) written notice of the consummation of the SeaSpine Transactions (including notice whether the SeaSpine Transactions were consummated as an SeaSpine Domestic Transaction or an SeaSpine Foreign Transaction), and
(B) an officer’s certificate in form and substance reasonably satisfactory to the Administrative Agent and signed by a Responsible Officer of the Borrower certifying (x) that, prior to the consummation of the SeaSpine Transactions,
there are no actions, suits, proceedings, investigations, litigation, claims, disputes or proceedings, pending or, to the knowledge of the Borrower, threatened or contemplated, at law, in equity, in arbitration or before any Governmental Authority,
by or against the Borrower or any of its Subsidiaries or against any of their respective properties or any orders, decrees, judgments, rulings injunctions writs, temporary restraining orders or other orders of any nature issued by any court or
Governmental Authority that purport to enjoin or restrain the performance of the SeaSpine 

 
Transactions and (y) compliance with the limitations set forth in the provisos to the definition of “SeaSpine Business Assets” and with this Section 7.06(n), including
the calculation of compliance with the total asset test described in such definition and with clauses (a) and (b) of Section 7.17 on a Pro Forma Basis, the Borrower and its Subsidiaries may consummate the SeaSpine Dividend
Transactions.” 
 (j) Amendment to Section 7.08. The proviso of Section 7.08 of the Credit Agreement is
hereby deleted in its entirety and replaced with the following (for ease of reference, changes from the existing definition are reflected in the blackline below): 

“provided that the Borrower and its Subsidiaries may engage in (a) the SeaSpine Transactions, (b) Investments
made to SpinCo and its Subsidiaries (after giving effect to the SeaSpine Transactions) to the extent permitted by Sections 7.02(m) and 7.09 and (c) activities ancillary, related or complementary to the business currently carried on at the
Closing Date.” 
 (k) Amendment to Section 7.09. Each of clauses (i) and (ii) of the
proviso of Section 7.09 of the Credit Agreement is hereby amended by inserting “(including the SeaSpine Transactions to the extent not otherwise prohibited hereunder)” at the end of each such clause, and the following new clause
(vi) is added to the end of such proviso: “or (vi) transactions between Loan Parties and Excluded Subsidiaries that are consummated and all obligations of the parties thereunder satisfied or terminated on or before the date of the
SeaSpine Dividend Transactions solely for the purpose of consummating the SeaSpine Transactions otherwise permitted hereunder. 
 SECTION
1.02. Representations and Warranties. The Borrower hereby represents and warrants to the Administrative Agent and the Lenders, as follows: 

(a) The representations and warranties set forth in Article V of the Credit Agreement and in each other Loan Document are true
and correct in all material respects (or, if such representation or warranty is by its terms qualified by concepts of materiality or reference to Material Adverse Effect, such representation or warranty shall be true and correct in all respects) as
of the First Amendment Effective Date (as defined below) with the same effect as though made on and as of the First Amendment Effective Date, except that to the extent such representations and warranties expressly relate to an earlier date (in which
case such representations and warranties shall be true and correct in all material respects on and as of such earlier date) or to the extent such representations and warranties expressly relate to the specified supplemental schedules updated and
delivered to the Administrative Agent in accordance with the most recent quarterly Compliance Certificate (in which case such representations and warranties shall be true and correct in all material respects on and as the date of the most recent
Compliance Certificate). For purposes of this Amendment, the representations and warranties contained in subsections (a) and (b) of Section 5.05 of the Credit Agreement shall be deemed to refer to the most recent statements
furnished pursuant to subsections (a) and (b), respectively, of Section 6.01 of the Credit Agreement. 

 (b) On the First Amendment Effective Date, no Default or Event of Default has
occurred and is continuing or will result from this Amendment. 
 (c) The execution, delivery and performance of this
Amendment by the Borrower have been duly authorized by all requisite corporate or other organizational action. 
 (d) This
Amendment constitutes the legal, valid and binding obligation of the Borrower enforceable against the Borrower in accordance with its terms, subject to equitable principles and Debtor Relief Laws. 

(e) The execution, delivery and performance of this Amendment by the Borrower do not and will not (i) contravene the terms
of any of the Borrower’s Organization Documents; (ii) conflict with or result in any breach or contravention of, or (except for the Liens created under the Loan Documents) the creation of any Lien under, or require any payment to be made
under (A) any Contractual Obligation to which the Borrower or any Loan Party is a party or affecting the Borrower or any Subsidiary or the properties of the Borrower or any of its subsidiaries or (B) any order, injunction, writ or decree
of any Governmental Authority or any arbitral award to which the Borrower or its property is subject; or (iii) violate any Law. 

SECTION 1.03. Amendment Effectiveness. This Amendment shall become effective only upon satisfaction (or waiver by the Required Lenders)
of all of the following conditions precedent (the first date upon which each such condition has been satisfied being herein called the “First Amendment Effective Date”): 

(a) The Administrative Agent shall have received duly executed counterparts of this Amendment which, when taken together, bear
the authorized signatures of the Borrower and the Consenting Lenders (which shall represent at least the Required Lenders). 

(b) The Administrative Agent shall have received certification from the Borrower, dated as of the proposed First Amendment
Effective Date, that the representations and warranties set forth in Section 1.02 hereof are true and correct. 

(c) The Administrative Agent shall have received all fees and expenses required to be paid by the Borrower pursuant to
Section 1.06 of this Amendment. 
 (d) The Lenders shall have received such other documents, instruments and
certificates as they shall reasonably request and such other documents, instruments and certificates shall be reasonably satisfactory in form and substance to the Lenders and their counsel. All corporate and other proceedings taken or to be taken in
connection with this Amendment and all documents incidental thereto, whether or not referred to herein, shall be reasonably satisfactory in form and substance to the Administrative Agent and its counsel. 

SECTION 1.04.FATCA. For purposes of determining withholding Taxes imposed under the Foreign Account Tax Compliance Act (FATCA), from and
after the effective date of 

 
the Amendment, the Borrower and the Administrative Agent shall treat (and the Lenders hereby authorize the Administrative Agent to treat) the Credit Agreement as not qualifying as a
“grandfathered obligation” within the meaning of Treasury Regulation Section 1.1471-2(b)(2)(i). 
 SECTION 1.05.
APPLICABLE LAW. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT REFERENCE TO THE CONFLICTS OF LAWS PRINCIPLES THEREOF. 

SECTION 1.06. Fees and Expenses. The Borrower shall pay all reasonable out-of-pocket expenses incurred by the Administrative Agent in
connection with the preparation, negotiation, execution, delivery and enforcement of this Amendment, including, but not limited to, the reasonable fees and disbursements of counsel. 

SECTION 1.07. Counterparts. This Amendment may be executed in any number of counterparts, each of which shall constitute an original
but all of which when taken together shall constitute but one agreement. Delivery by facsimile, .pdf, electronic mail or other electronic means by any of the parties hereto of an executed counterpart of this Amendment shall be as effective as an
original executed counterpart hereof and shall be deemed a representation that an original executed counterpart hereof will be delivered, but the failure to deliver a manually executed counterpart shall not affect the validity, enforceability or
binding effect of this Amendment. 
 SECTION 1.08. Loan Document. As of the date hereof, this Amendment shall constitute a “Loan
Document” under and in accordance with the Credit Agreement. 
 SECTION 1.09. Credit Agreement. Except as expressly set forth
herein, the amendments provided herein shall not by implication or otherwise limit, constitute a waiver of, or otherwise affect the rights and remedies of the Lenders or the Administrative Agent under the Credit Agreement or any other Loan Document,
nor shall they constitute a waiver of any Default or Event of Default, nor shall they alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other Loan
Document. Each of the amendments provided herein shall apply and be effective only with respect to the provisions of the Credit Agreement specifically referred to by such amendment. Except as expressly amended herein, the Credit Agreement shall
continue in full force and effect in accordance with the provisions thereof and is in all respects ratified and confirmed. As used in the Credit Agreement, the terms “Agreement”, “herein”, “hereinafter”,
“hereunder”, “hereto” and words of similar import shall include, from and after the First Amendment Effective Date, the Amended Agreement. 

[Remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
duly authorized officers, all as of the date first above written. 
  

			
	Borrower:
	
	 INTEGRA LIFESCIENCES HOLDINGS

CORPORATION, a Delaware corporation

		
	 By:
	 	 /s/ Glenn G. Coleman

		 	Name: Glenn G. Coleman
		 	 Title: Corporate Vice President and Chief Financial

Officer

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
duly authorized officers, all as of the date first above written. 
  

			
	BANK OF AMERICA, N.A., as Administrative Agent
		
	 By:
	 	 /s/ Joseph L. Corah

		 	Name: Joseph L. Corah
		 	Title: Director
	
	 BANK OF AMERICA, N.A., as Swing Line Lender, L/C

Issuer and as a Lender

		
	 By:
	 	 /s/ Joseph L Corah

		 	Name: Joseph L. Corah
		 	Title: Director

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
duly authorized officers, all as of the date first above written. 
  

			
	WELLS FARGO BANK, N.A., as a Lender
		
	 By:
	 	 /s/ Matthew Olson

		 	Name: Matthew Olson
		 	Title: Vice President

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
duly authorized officers, all as of the date first above written. 
  

			
	DNB Capital LLC, as a Lender
		
	 By:
	 	 /s/ Phil Kurpiewski

		 	Name: Phil Kurpiewski
		 	Title: Senior Vice President
		
	 By:
	 	 /s/ Geshu Sugandh

		 	Name: Geshu Sugandh
		 	Title: First Vice President

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
duly authorized officers, all as of the date first above written. 
  

			
	HSBC Bank USA, N.A., as a Lender
		
	 By:
	 	 /s/ Nicholas Lotz

		 	Name: Nicholas Lotz
		 	Title: Senior Vice President

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
duly authorized officers, all as of the date first above written. 
  

			
	Citizens Bank, N.A., as a Lender
		
	By:	 	 /s/ Thomas Walsh

		 	Name: Thomas Walsh
		 	Title: Assistant Vice President

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
duly authorized officers, all as of the date first above written. 
  

			
	Royal Bank of Canada, as a Lender
		
	By:	 	 /s/ Dean Sas

		 	Name: Dean Sas
		 	Title: Authorized Signatory

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
duly authorized officers, all as of the date first above written. 
  

			
	TD Bank, N.A., as a Lender
		
	By:	 	 /s/ Shreya Shah

		 	Name: Shreya Shah
		 	Title: Senior Vice President

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
duly authorized officers, all as of the date first above written. 
  

			
	 CREDIT AGRICOLE CORPORATE AND

INVESTMENT BANK, as a Lender

		
	By:	 	 /s/ Thomas Randolph

		 	Name: Thomas Randolph
		 	Title: Managing Director
		
	By:	 	 /s/ Amy Trapp

		 	Name: Amy Trapp
		 	Title: Managing Director

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their
duly authorized officers, all as of the date first above written. 
  

			
	Capital One, National Association, as a Lender
		
	By:	 	 /s/ Thomas L. Savage

		 	Name: Thomas L. Savage
		 	Title: Vice President

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their duly authorized
officers, all as of the date first above written. 
  

			
	MORGAN STANLEY BANK, N.A., as a Lender
		
	By:	 	 /s/ Allen Chang

		 	Name: Allen Chang
		 	Title: Authorized Signatory

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their duly authorized
officers, all as of the date first above written. 
  

			
	 MORGAN STANLEY SENIOR FUNDING, INC., as a

Lender

		
	By:	 	 /s/ Allen Chang

		 	Name: Allen Chang
		 	Title: Vice President

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their duly authorized
officers, all as of the date first above written. 
  

			
	MUFG Union Bank N.A., as a Lender
		
	By:	 	 /s/ Hermogenes (Al) Torres

		 	Name: Hermogenes (Al) Torres
		 	Title: Director

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their duly authorized
officers, all as of the date first above written. 
  

			
	FIFTH THIRD BANK, as a Lender
		
	By:	 	 /s/ Tamara Dowd

		 	Name: Tamara Dowd
		 	Title: Vice President

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their duly authorized
officers, all as of the date first above written. 
  

			
	JPMORGAN CHASE BANK, N.A., as a Lender
		
	By:	 	 /s/ Deborah R. Winkler

		 	Name: Deborah R. Winkler
		 	Title: Vice President

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their duly authorized
officers, all as of the date first above written. 
  

			
	PNC Bank, N.A., as a Lender
		
	By:	 	 /s/ Sharon Landgraf

		 	Name: Sharon Landgraf
		 	Title: Senior Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]